Abstract:Poster session 1, September 21, 2022, 12:30 PM - 1:30 PMObjectivesFluconazole is widely used to treat invasive fungal infections, but the fluconazole resistance of pathogenic fungi undermines its antifungal efficacy. Although voriconazole has a good anti- Aspergillus fumigatus activity, it is not a first-line drug for treating infections caused by Candida and Cryptococcus species. To meet the demand for new azoles, in our previous studies, we identified a new azoles compound, YZJT-1903 (Fig. 1e), and found that YZJT-1903 has a longer in vivo half-life (˃10 days in rat) and a wider therapeutic window than voriconazole, indicating that YZJT-1903 is a promising azoles compound to treat invasive fungal infections. In this study, we further investigated antifungal activity of YZJT-1903 compared with fluconazole and voriconazole.MethodsWe investigated the antifungal spectrum of YZJT-1903 and minimum inhibitory concentration (MIC) and accumulative antifungal percentage of YZJT-1903 against various pathogenic fungi using microbroth dilution method. We quantitatively analyzed the inhibitory effect of YZJT-1903 on fungal growth by the Time-Growth Curve assay. Mutation Preventative Concentration (MPC) was carried out to verify the antifungal potential of YZJT-1903. Sterols of plasma membrane were extracted and the composition was analyzed through Gas Chromatograph-Mass Spectrometer (GC-MS) to verify the classical action mechanism of azoles.ResultsOur MIC assay results demonstrated that YZJT-1903 has a broad antifungal spectrum and can significantly inhibit the growth of A. fumigatus, Cryptococcus neoformans, Cryptococcus gatti , and Candida species (such as Candida albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. guilliermondii , and C. auris ) (Fig. 1a). We found that the antifungal activity of YZJT-1903 is equivalent to that of voriconazole, but superior to that of fluconazole (Fig. 1a). Accumulative antifungal percentage can directly reflect this relationship quantitatively among YZJT-1903, fluconazole, and voriconazole due to the curve of YZJT-1903 has no significance with voriconazole (Fig. 1b). YZJT-1903 (0.25 μ g/ml) has similar inhibitory effect to voriconazole (0.25 μ g/ml) on the growth of C. albicans and C. neoformans , but has the best inhibitory effect on C. auris [compared with voriconazole (0.25 μ g/ml), and fluconazole (0.25 μ g/ml)] (Fig. 1c). MPC of YZJT-1903 in C. neoformans is as low as 0.25 μ g/ml which means YZJT-1903 at low concentration can already prevent the drug-resistant mutation of strains, therefore, avoid the occurrence of resistance in Cryptococcus spp. (Fig. 1d). Extraction of sterols showed that the fungal cell treated with YZJT-1903 at 0.063 μ g/ml have completely no detectable ergosterol which is similar to the group of fluconazole at 4 μ g/ml, and the group of voriconazole at 0.031 μ g/ml (Fig. 2). This result gave a hint that maybe the property of YZJT-1903 is more similar to voriconazole which may matter with the structure of these two compounds. We found that feeding exogenous 100 μ m ergosterol counteracted the antifungal activity of YZJT-1903, indicating that YZJT-1903 has an antifungal activity by inhibiting the synthesis of ergosterol.ConclusionOur study demonstrates that YZJT-1903 has a potent antifungal activity, which will contribute to addressing devastating global invasive fungal infections caused by Candida and Cryptococcus species.

In Vitro and in Vivo Activities of HQQ-3, a New Triazole Antifungal Agent

Biological activity of a novel quinoline compound ZJ5337

Antifungal Activity of 3-Hydrazinoquinoxaline-2-Thiol, a Novel Quinoxaline Derivative against Candida Species

P063 Research on antifungal activity of a new azoles compound, YZJT-1903

In Vitro Activities of the Tetrazole VT-1161 Compared with Itraconazole and Fluconazole Against Cryptococcus and Non-Albicans Candida Species

Antifungal activity and potential mechanism of action of Huangqin decoction against Trichophyton rubrum

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Synthesis and Antifungal Activity of 3-Methyl-4-amino-5-mercapto-1,2,4-triazole Derivatives

Design, synthesis, and evaluation of novel tetrazoles featuring isoxazole moiety as highly selective antifungal agents

Design, Synthesis, and In Vitro and In Vivo Antifungal Activity of Novel Triazoles Containing Phenylethynyl Pyrazole Side Chains

Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Discovery of Novel Tetrazoles Featuring a Pyrazole Moiety as Potent and Highly Selective Antifungal Agents

Design, Synthesis and Antifungal Evaluation of 1-(2-(2,4-Difluorophenyl)-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)-1h-1,2,4-triazol-5(4h)-one

Discovery of novel triazoles containing benzyloxy phenyl isoxazole side chain with potent and broad-spectrum antifungal activity

Triazole Derivatives with Improved in Vitro Antifungal Activity over Azole Drugs

Design, synthesis, and in vitro evaluation of novel antifungal triazoles containing substituted 1,2,3-triazole-methoxyl side chains

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives

Synthesis, in Vitro Evaluation and Molecular Docking Studies of New Triazole Derivatives As Antifungal Agents.

Anti- Candida Activity of New Azole Derivatives Alone and in Combination with Fluconazole

Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates.

In Vitro Antifungal Activity of ZJ-522, a New Triazole Restructured from Fluconazole and Butenafine, Against Clinically Important Fungi in Comparison with Fluconazole and Butenafine.